LifeSci Capital downgraded Repare Therapeutics (RPTX) to Market Perform from Outperform.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPTX:
- Repare Therapeutics price target lowered to $4 from $9 at Stifel
- Closing Bell Movers: RH soars 20% on earnings, guidance raise
- Repare Therapeutics Shows Promise in Cancer Drug Trials
- Repare Therapeutics reports ‘positive’ results from MYTHIC Phase 1 trial
- Repare Therapeutics announces CRADA to advance camonsertib development